9 Biosimilar Takeaways from the 2018 EULAR Congress

Biosimilars featured prominently in research presented at the European League Against Rheumatism's Annual European Congress of Rheumatology. Here are 9 key takeaways from the meeting.

Related Content:

EULARConference

Follow-On Biologics Poised to Expand Global Health Care Access and Lower Costs

Yesintek Biosimilar Shows Comparable Efficacy, Lower Immunogenicity Than Stelara, Says Elena Wolff-Holz, MD

Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow